News

In the first step towards this overall goal of creating two independent companies, Akzo said that it would seek a minority listing of its pharmaceuticals business, to be

CAT said that Humira achieved sales of $1.4 billion in 2005. As a result, the drug became the first product from the UK biotech industry to reach blockbuster

The studies of the drug in familial hypercholesterolemia (FH) are part of a wider developmental program for the drug as a treatment for high cholesterol. ISIS 301012 reduces

These are in addition to two targets Abbott selected for advancement in April 2005. Abbott now has a total of four targets under investigation from the strategic collaboration

Originating from Arrow’s focused chemical library and optimized in-house, the compound has shown potent activity in the replicon assay and has an excellent therapeutic index and good pharmacokinetic

“Under-treatment of cholesterol disorders is a major public health challenge,” said lead author Dr David Goff Jr. “In our study of middle-age and older adults with no symptoms

The findings could enable the current supply of the drug – now extracted from animal tissue – to be replaced or supplemented by the synthetic version. The new

The company is now developing the drug in an MS indication, although for the past 16 years the drug has been marketed in Japan and South Korea as

The award will fund Dr Ruolan Liu’s investigation of natural-killer-T (NKT) cell treatment for Myasthenia Gravis (MG) and other autoimmune diseases. Since joining Barrow’s Neuroimmunology Research Laboratory in